NCT02304159View on ClinicalTrials.gov

Study to Evaluate the Safety and Efficacy of Daclatasvir/Sofosbuvir/Ribavirin for 16 Versus 24 Weeks for HCV Genotype 3 Cirrhotics

PHASE4CompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

August 31, 2017

Study Completion Date

August 31, 2017

Conditions
Hepatitis CCirrhosis
Interventions
DRUG

daclatasvir

DRUG

Sofosbuvir, Sovaldi

DRUG

Ribavirin

Trial Locations (1)

92118

Southern California Research Center, Coronado

All Listed Sponsors
lead

Tarek I. Hassanein, M.D., FACP, FAG, AGAF

OTHER

NCT02304159 - Study to Evaluate the Safety and Efficacy of Daclatasvir/Sofosbuvir/Ribavirin for 16 Versus 24 Weeks for HCV Genotype 3 Cirrhotics | Biotech Hunter | Biotech Hunter